Our present study attempts to test for the sensitivity of the MRD “lite” panel using CD38, CD10, CD19, CD34, and CD45 for the diagnosis of residual disease in B-cell acute lymphoblastic leukemia (B-ALL). This evidence concerns the gene CD34 and acute lymphoblastic leukemia.